Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis?: Results from the Nurses' Health Study
Corresponding Author
Elizabeth W. Karlson
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
75 Francis Street, Boston, MA 02115Search for more papers by this authorLisa A. Mandl
Hospital for Special Surgery, Cornell Weill Medical College, New York, New York
Search for more papers by this authorSusan E. Hankinson
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
Search for more papers by this authorFrancine Grodstein
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
Search for more papers by this authorCorresponding Author
Elizabeth W. Karlson
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
75 Francis Street, Boston, MA 02115Search for more papers by this authorLisa A. Mandl
Hospital for Special Surgery, Cornell Weill Medical College, New York, New York
Search for more papers by this authorSusan E. Hankinson
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
Search for more papers by this authorFrancine Grodstein
Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts
Search for more papers by this authorAbstract
Objective
To explore the contribution of female hormonal factors occurring prior to the onset of rheumatoid arthritis (RA), such as age at menarche, parity, age at first birth, breast-feeding, use of oral contraceptives (OCs), irregular menstrual cycles, and postmenopausal hormone (PMH) use, to the subsequent development of RA in a large female cohort.
Methods
We studied female reproductive and hormonal risk factors for RA in a cohort of 121,700 women enrolled in the longitudinal Nurses' Health Study. The diagnosis of incident RA (between 1976 and 2002) in 674 women was confirmed by a connective tissue disease screening questionnaire and blinded medical record review for American College of Rheumatology criteria. Sixty percent of the patients with RA were rheumatoid factor positive. The relationship between potential risk factors, including age, age at menarche, parity, age at first birth, total lifetime history of breast-feeding, use of OCs, and irregular menstrual cycles and the multivariate-adjusted risk of RA was estimated using Cox proportional hazards models.
Results
Using a multivariate model that adjusted for age, body mass index, smoking, parity, and other hormonal factors, we observed a strong trend for decreasing risk of RA with increasing duration of breast-feeding (P for trend = 0.001). For women who breast-fed (compared with parous women who did not breast-feed), the risk ratios (RRs) and 95% confidence intervals (95% CIs) were as follows: breast-feeding for ≤3 total months, RR 1.0 (95% confidence interval [95% CI] 0.8-1.2); for 4–11 total months, RR 0.9 (95% CI 0.7–1.1); for 12–23 total months, RR 0.8 (95% CI 0.6–1.0); and for ≥24 total months, RR 0.5 (95% CI 0.3–0.8). Very irregular menstrual cycles were associated with an increased risk of RA (RR 1.4, 95% CI 1.0–2.0). Age at menarche ≤10 years was associated with an increased risk of seropositive RA (RR 1.6, 95% CI 1.1–2.4) but not significantly associated with risk of RA. Parity, total number of children, age at first birth, and OC use were not associated with an increased risk of RA in this cohort.
Conclusion
In this large cohort, breast-feeding for >12 months was inversely related to the development of RA. This apparent effect was dose-dependent, with a significant trend toward lower risk with longer duration of breast-feeding. Irregular menstrual cycles and earlier age at menarche increased the risk of RA. Other reproductive hormonal factors were not associated with RA risk.
REFERENCES
- 1 Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111: 87–98.
- 2 Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735–9.
- 3 Masi AT, Feigenbaum SL, Chatterton RT. Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Semin Arthritis Rheum 1995; 25: 1–27.
- 4 Cutolo M, Accardo S. Sex hormones, HLA and rheumatoid arthritis. Clin Exp Rheumatol 1991; 9: 641–6.
- 5 Gordon D, Beastall GH, Thomson JA, Sturrock RD. Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Br J Rheumatol 1988; 27: 440–4.
- 6 Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990; 17: 1620–2.
- 7 Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 10–2.
- 8 Wilder RL, Elenkov IJ. Hormonal regulation of tumor necrosis factor-α, interleukin-12 and interleukin-10 production by activated macrophages: a disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann N Y Acad Sci 1999; 876: 14–31.
- 9 Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 1992; 35: 152–5.
- 10 Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994; 37: 808–13.
- 11 Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis 1996; 55: 94–8.
- 12 Brennan P, Silman AJ. An investigation of gene-environment interaction in the etiology of rheumatoid arthritis. Am J Epidemiol 1994; 140: 453–60.
- 13 Brun JG, Nilssen S, Kvale G. Breast feeding, other reproductive factors and rheumatoid arthritis: a prospective study. Br J Rheumatol 1995; 34: 542–6.
- 14 Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 2003; 33: 72–82.
- 15 Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol 2004; 31: 207–13.
- 16 Spector TD, Roman E, Silman AJ. The pill, parity, and rheumatoid arthritis. Arthritis Rheum 1990; 33: 782–9.
- 17 Brennan P, Bankhead C, Silman A, Symmons D. Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 1997; 26: 817–23.
- 18 Hazes JM, Dijkmans BC, Vandenbroucke JP, de Vries RR, Cats A. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum 1990; 33: 173–9.
- 19 Vandenbroucke JP, Witteman JC, Valkenburg HA, Boersma JW, Cats A, Festen JJ, et al. Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA 1986; 255: 1299–303.
- 20 Allebeck P, Ahlbom A, Ljungstrom K, Allander E. Do oral contraceptives reduce the incidence of rheumatoid arthritis? A pilot study using the Stockholm County medical information system. Scand J Rheumatol 1984; 13: 140–6.
- 21 Vandenbroucke JP, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Huber-Bruning O, et al. Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect. Lancet 1982; 2: 839–42.
- 22 Wingrave SJ, Kay CR. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet 1978; 1: 569–71.
- 23 Deighton CM, Sykes H, Walker DJ. Rheumatoid arthritis, HLA identity, and age at menarche. Ann Rheum Dis 1993; 52: 322–6.
- 24 Hernandez-Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Exogenous sex hormones and the risk of rheumatoid arthritis. Arthritis Rheum 1990; 33: 947–53.
- 25 Hannaford PC, Kay CR, Hirsch S. Oral contraceptives and rheumatoid arthritis: new data from the Royal College of General Practitioners' oral contraception study. Ann Rheum Dis 1990; 49: 744–6.
- 26 Del Junco DJ, Annegers JF, Luthra HS, Coulam CB, Kurland LT. Do oral contraceptives prevent rheumatoid arthritis? JAMA 1985; 254: 1938–41.
- 27 Linos A, Worthington JW, O'Fallon WM, Kurland LT. Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1983; 1: 1299–300.
- 28 Hernandez Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1990; 1: 285–91.
- 29 Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46: 625–31.
- 30 Spector TD, Brennan P, Harris P, Studd JW, Silman AJ. Does estrogen replacement therapy protect against rheumatoid arthritis? J Rheumatol 1991; 18: 1473–6.
- 31 Carette S, Marcoux S, Gingras S. Postmenopausal hormones and the incidence of rheumatoid arthritis. J Rheumatol 1989; 16: 911–3.
- 32 Koepsell TD, Dugowson CE, Nelson JL, Voigt LF, Daling JR. Non-contraceptive hormones and the risk of rheumatoid arthritis in menopausal women. Int J Epidemiol 1994; 23: 1248–55.
- 33 Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 1997; 6: 49–62.
- 34 Karlson EW, Sanchez-Guerrero J, Wright EA, Lew EA, Daltroy LH, Katz LN, et al. A connective tissue disease screening questionnaire for population studies. Ann Epidemiol 1995; 5: 297–302.
- 35 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
- 36 Mikuls TR, Cerhan JR, Criswell LA, Merlino L, Mudano AS, Burma M, et al. Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2002; 46: 83–91.
- 37 SAS/STAT user's guide: version 6, 4th ed. Cary, NC: SAS Institute; 1990.
- 38 Spector TD, Roman E, Silman AJ. A UK case-control study on the effect of parity and the oral contraceptive pill on the development of rheumatoid arthritis. Br J Rheumatol 1989; 28 Suppl 1: 32; discussion 42–5.
- 39 Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 1990; 33: 1770–5.
- 40 Romieu I, Hernandez-Avila M, Liang MH. Oral contraceptives and the risk of rheumatoid arthritis: a meta-analysis of a conflicting literature. Br J Rheumatol 1989; 28 Suppl 1: 13–7; discussion 18–23.
- 41 Kay CR, Wingrave SJ. Oral contraceptives and rheumatoid arthritis [letter]. Lancet 1983; 1: 1437.
- 42 Del Junco DJ, Annegers JF, Coulam CB, Luthra HS. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol 1989; 28 Suppl 1: 33; discussion 42–5.
- 43 Silman AJ. Parity status and the development of rheumatoid arthritis. Am J Reprod Immunol 1992; 28: 228–30.
- 44 Engel A. Rheumatoid arthritis in US adults 1960-62. In: PH Bennett, HN Wood, editors. Population studies of the rheumatic diseases. Amsterdam: Exerpta Medica; 1968. p. 83–92.
- 45 Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women: incidence rates in Group Health Cooperative, Seattle, Washington, 1987–1989. Arthritis Rheum 1991; 34: 1502–7.
- 46 Masi AT. Incidence of rheumatoid arthritis: do the observed age-sex interaction patterns support a role of androgenic-anabolic steroid deficiency in its pathogenesis? Br J Rheumatol 1994; 33: 697–9.
- 47 Booji A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 811–5.
- 48 Cutolo M, Balleari E, Giusti M, Intra E, Accardo S. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1–5.
- 49 Berczi I, Nagy E, Asa SL, Kovacs K. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682–8.
- 50 Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26: 118–23.
- 51 Lavalle C. Prolactin: a hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic diseases. J Rheumatol 1992; 19: 839–41.
- 52 Gagnerault MC, Touraine P, Savino W, Kelly PA, Dardenne M. Expression of prolactin receptors in murine lymphoid cells in normal and autoimmune situations. J Immunol 1993; 150: 5673–81.
- 53 Nagafuchi H, Suzuki N, Kaneko A, Asai T, Sakane T. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1890–900.
- 54 Matera L, Contarini M, Bellone G, Forno B, Biglino A. Up-modulation of interferon-γ mediates the enhancement of spontaneous cytotoxicity in prolactin-activated natural killer cells. Immunology 1999; 98: 386–92.
- 55 Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-γ by natural killer and T cells. Ann N Y Acad Sci 2000; 917: 505–13.
- 56 Vidaller A, Guadarrama F, Llorente L, Mendez JB, Larrea F, Villa AR, et al. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol 1992; 12: 210–5.
- 57 Vidaller A, Llorente L, Larrea F, Mendez JP, Alcocer-Varela J, Alarcon-Segovia D. T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. Clin Immunol Immunopathol 1986; 38: 337–43.
- 58 Matalka KZ. Prolactin enhances production of interferon-γ, interleukin-12, and interleukin-10, but not of tumor necrosis factor-α, in a stimulus-specific manner. Cytokine 2003; 21: 187–94.
- 59 Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281–8.
- 60 Cutolo M. Do sex hormones modulate the synovial macrophages in rheumatoid arthritis? Ann Rheum Dis 1997; 56: 281–4.
- 61 Straub RH, Paimela L, Peltomaa R, Schölmerich J, Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum 2002; 46: 654–62.
- 62 Lankarani-Fard A, Kritz-Silverstein D, Barrett-Connor E, Goodman-Gruen D. Cumulative duration of breast-feeding influences cortisol levels in postmenopausal women. J Womens Health Gend Based Med 2001; 10: 681–7.
- 63 Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, et al. IL-12, TNF-α, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001; 86: 4933–8.
- 64 Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122: 1978–85.
- 65 Gomez F, Ruiz P, Briceno F, Lopez R, Michan A. Treatment with progesterone analogues decreases macrophage Fcγ receptors expression. Clin Immunol Immunopathol 1998; 89: 231–9.
- 66 Szekeres-Bartho J, Barakonyi A, Par G, Polgar B, Palkovics T, Szereday L. Progesterone as an immunomodulatory molecule. Int Immunopharmacol 2001; 1: 1037–48.
- 67 Ito A, Imada K, Sato T, Kubo T, Matsushima K, Mori Y. Suppression of interleukin 8 production by progesterone in rabbit uterine cervix. Biochem J 1994; 301(Pt 1): 183–6.
- 68 Brennan P, Ollier B, Worthington J, Hajeer A, Silman A. Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Lancet 1996; 348: 106–9.
